LENZ LENZ Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$7.01

Period return

-19.70 (-73.76%)

Volume

494.6K

2026-06-05O $7.19 H $7.36 L $6.92 C $7.01MA5 $7.16MA20 $7.68MA60 $9.11MA120 $12.32

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 14.LowBUY24 days ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 12.LowBUY25 days ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 12.MediumHOLD25 days ago
Piper Sandler: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $32

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Solana Beach, CA, United States
Fiscal year end: —
Employees: 152
IPO date: —

View details →